Showing 701-710 of 1922 results for "".
Overcoming Treatment Plateaus in Chronic DME
https://modernod.com/specialty/retina/Overcoming-Treatment-Plateaus-in-Chronic-DME-2506/33190/Learn about a patient with a 9-year history of injections for treatment of retinal disease and the final approach resulting in positive outcomes.First Commerical Surgeries Performed with MacTel Therapy
https://modernod.com/podcasts/eyewire-news-the-podcast/first-commerical-surgeries-performed-with-mactel-therapy/37097/Charles Wykoff, MD, PhD, shares his experience performing the first commercial case for a patient with MacTel; VSY Biotechnology launches its Enova Hydrophobic IOLs with a new preloaded delivery system; and an app is launched that syncs AI directly to leading OCT devices. Learn more about your ad ch93. Thriving, Not Just Surviving: A Mental Health Check-In for New Grads ft. Dr. Meenal Agarwal
https://modernod.com/podcasts/four-eyes/93-thriving-not-just-surviving-a-mental-health-check-in-for-new-grads-ft-dr-meenal-agarwal/37043/In this refreshingly honest episode, we chat with Dr. Meenal Agarwal, an Optometrist and private practice owner, about the mental health challenges that often come with life after optometry school.Geared toward students and new grads, this conversation covers:•What burnout really feels like and whenTryptyr Now Available in US
https://modernod.com/podcasts/eyewire-news-the-podcast/tryptyr-now-available-in-us/37095/Alcon launches its recently approved dry eye drug Tryptyr; a potential $1 billion deal is made to advance extended-release therapies for eye diseases; and two companies with late-stage AMD drug candidates complete phase 3 enrollment. Learn more about your ad choices. Visit megaphone.fm/adchoicesHarrow Adds Biosimilars to US Portfolio
https://modernod.com/podcasts/eyewire-news-the-podcast/harrow-adds-biosimilars-to-us-portfolio/37094/Harrow enters a deal to expand it biosimilar pharma portfolio; the first gene-agnostic therapy to restore vision in RP patients advances; and Aldeyra provides an update on its dry eye drug candidate reproxalap. Learn more about your ad choices. Visit megaphone.fm/adchoicesFirst Myopia Drug Approved in Europe
https://modernod.com/podcasts/eyewire-news-the-podcast/first-myopia-drug-approved-in-europe/37088/The first pharmaceutical treatment for myopia is approved in Europe; the FDA sets a target action date for a first-of-its-kind presbyopia drop; and John Berdahl, MD, discusses the reimbursement landscape in ophthalmology. Learn more about your ad choices. Visit megaphone.fm/adchoicesB+L Receives Approval in Europe for LuxLife IOL
https://modernod.com/podcasts/eyewire-news-the-podcast/bl-receives-approval-in-europe-for-luxlife-iol/37084/Bausch + Lomb receives CE Mark for a new full range of vision IOL; Aldeyra plans to once again resubmit a new drug application to the FDA for dry eye drug candidate reproxalap; and Topcon makes several deals to advance its AI and digital health solutions Learn more about your ad choices. Visit megOphthalmic Leaders Launch SightLine Meeting
https://modernod.com/podcasts/eyewire-news-the-podcast/ophthalmic-leaders-launch-sightline-meeting/37083/Commercial stakeholders discuss the challenges and opportunities in ophthalmology in this special edition of Eyewire News: The Podcast. Learn more about your ad choices. Visit megaphone.fm/adchoices68. Oh, the Places You’ll Go… as a New Grad ft. Dr. Alexa Hecht
https://modernod.com/podcasts/four-eyes/68-oh-the-places-youll-go-as-a-new-grad-ft-dr-alexa-hecht/37018/Amrit and Deepon sit down with Dr. Alexa Hecht, a new grad Optometrist from the University of Waterloo School of Optometry, to talk about her journey into practicing. Alexa shares the ups and downs of working in multiple practice locations six days a week, and how this work-life “imbalance” took a tIntroducing Premium Products and Services to Patients
https://modernod.com/topics/business/introducing-premium-products-and-services-to-patients/38553/Advice to make you feel more confident about offering this important aspect of clinical care.